Pharmacologic modulation strategies to reduce dose requirements of anticancer therapy while preserving clinical efficacy

Future Oncology

Volumn 8, Issue 6, 2012, Pages 731-749

  Zee, Ying Kiat ^a   Goh, Boon Cher ^a,b   Lee, Soo Chin ^a,b  

^a NATIONAL UNIVERSITY HEALTH SYSTEM   (Singapore)

^b NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

Author keywords

drug interactions; drug transporters; drug metabolizing enzymes; inducers; inhibitors; pharmacokinetic interactions; pharmacologic modulation

Indexed keywords

5 ETHYNYLURACIL; ABC TRANSPORTER; ANTINEOPLASTIC AGENT; CYCLOSPORIN; CYTOCHROME P450 3A4; DOCETAXEL; ELACRIDAR; ETOPOSIDE; FIRTECAN; FLUOROURACIL; FOLINIC ACID; INDINAVIR; IRINOTECAN; KETOCONAZOLE; LOPINAVIR; PACLITAXEL; PHENOBARBITAL; RITONAVIR; SAQUINAVIR; TOPOTECAN; VALSPODAR;

BLOOD TOXICITY; BREAST CANCER; CANCER CHEMOTHERAPY; DIARRHEA; DOSE RESPONSE; DRUG BIOAVAILABILITY; DRUG EFFICACY; DRUG EXPOSURE; DRUG METABOLISM; ENZYME INHIBITION; FATIGUE; HUMAN; NAUSEA; NEUTROPENIA; PRIORITY JOURNAL; PROSTATE CANCER; REVIEW; UNSPECIFIED SIDE EFFECT; VOMITING;

ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; ATP-BINDING CASSETTE TRANSPORTERS; HUMANS; NEOPLASMS; TREATMENT OUTCOME;

EID: 84863683368     PISSN: 14796694     EISSN: 17448301     Source Type: Journal    
DOI: 10.2217/fon.12.53     Document Type: Review

References (76)

1. Goldie JH, Coldman AJ. A mathematic model for relating the drug sensitivity of tumors to their spontaneous mutation rate. Cancer Treat. Rep. 63(11-12), 1727-1733 (1979).
2. Perry MC. Principles of chemotherapy. In: THE Chemotherapy Source Book. Lippincott Williams & Wilkins, PA, USA, 31 (2008).
3. Srinivas NR. Is there a place for drug combination strategies using clinical pharmacology attributes? - Review of current trends in research. Curr. Clin. Pharmacol. 4(3), 220-228 (2009).
4. Charatan F. News feature: Costly US anticancer drugs pose problems for doctors and patients. BMJ 337, a778 (2008).
5. Mathias AA, West S, Hui J, Kearney BP. Dose-response of ritonavir on hepatic CYP3A activity and elvitegravir oral exposure. Clin. Pharmacol. Ther. 85(1), 64-70 (2009).
6. Zeldin RK, Petruschke RA. Pharmacological and therapeutic properties of ritonavir-boosted protease inhibitor therapy in HIV-infected patients. J. Antimicrob. Chemother. 53(1), 4-9 (2004).
7. Mangum EM, Graham KK. Lopinavir-ritonavir: A new protease inhibitor. Pharmacotherapy 21(11), 1352-1363 (2001).
8. Hill G, Cihlar T, Oo C et al. The anti-influenza drug oseltamivir exhibits low potential to induce pharmacokinetic drug interactions via renal secretion - correlation of in vivo and in vitro studies. Drug Metab. Dispos. 30(1), 13-19 (2002).
9. Holodniy M, Penzak SR, Straight TM et al. Pharmacokinetics and tolerability of oseltamivir combined with probenecid. Antimicrob. Agents Chemother. 52(9), 3013-3021 (2008).
10. Kivisto KT, Kroemer HK, Eichelbaum M. The role of human cytochrome P450 enzymes in the metabolism of anticancer agents: Implications for drug interactions. Br. J. Clin. Pharmacol. 40(6), 523-530 (1995).
11. Li AP, Kaminski DL, Rasmussen A. Substrates of human hepatic cytochrome P450 3A4. Toxicology 104(1-3), 1-8 (1995).
12. Wrighton SA, Brian WR, Sari MA et al. Studies on the expression and metabolic capabilities of human liver cytochrome P450IIIA5 (HLp3). Mol. Pharmacol. 38(2), 207-213 (1990).
13. De Wildt SN, Kearns GL, Leeder JS, van den Anker JN. Cytochrome P450 3A: Ontogeny and drug disposition. Clin. Pharmacokinet. 37(6), 485-505 (1999).
14. King CD, Rios GR, Green MD, Tephly TR. UDP-glucuronosyltransferases. Curr. Drug Metab. 1(2), 143-161 (2000).
15. Zhou SF. Drugs behave as substrates, inhibitors and inducers of human cytochrome P450 3A4. Curr. Drug Metab. 9(4), 310-322 (2008).
16. Ferguson RM, Sutherland DE, Simmons RL, Najarian JS. Ketoconazole, cyclosporin metabolism, and renal transplantation. Lancet 2(8303), 882-883 (1982).
17. First MR, Schroeder TJ, Weiskittel P, Myre SA, Alexander JW, Pesce AJ. Concomitant administration of cyclosporin and ketoconazole in renal transplant recipients. Lancet 2(8673), 1198-1201 (1989).
18. First MR, Schroeder TJ, Alexander JW et al. Cyclosporine dose reduction by ketoconazole administration in renal transplant recipients. Transplantation 51(2), 365-370 (1991).
19. Van Veldhuizen PJ, Reed G, Aggarwal A, Baranda J, Zulfiqar M, Williamson S. Docetaxel and ketoconazole in advanced hormone-refractory prostate carcinoma: A Phase I and pharmacokinetic study. Cancer 98(9), 1855-1862 (2003).
20. Engels FK, Ten Tije AJ, Baker SD et al. Effect of cytochrome P450 3A4 inhibition on the pharmacokinetics of docetaxel. Clin. Pharmacol. Ther. 75(5), 448-454 (2004).
21. Yong WP, Wang LZ, Tham LS et al. A Phase I study of docetaxel with ketoconazole modulation in patients with advanced cancers. Cancer Chemother. Pharmacol. 62(2), 243-251 (2008).
22. Bruno R, Hille D, Riva A et al. Population pharmacokinetics/ pharmacodynamics of docetaxel in Phase II studies in patients with cancer. J. Clin. Oncol. 16(1), 187-196 (1998).
23. Lim YW, Goh BC, Wang LZ et al. Pharmacokinetics and pharmacodynamics of docetaxel with or without ketoconazole modulation in chemonaive breast cancer patients. Ann. Oncol. 21(11), 2175-2182 (2010).
24. Gradishar WJ, Wedam SB, Jahanzeb M et al. Neoadjuvant docetaxel followed by adjuvant doxorubicin and cyclophosphamide in patients with stage III breast cancer. Ann. Oncol. 16(8), 1297-1304 (2005).
25. Amat S, Bougnoux P, Penault-Llorca F et al. Neoadjuvant docetaxel for operable breast cancer induces a high pathological response and breast-conservation rate. Br. J. Cancer 88(9), 1339-1345 (2003).
26. Kehrer DF, Mathijssen RH, Verweij J, De Bruijn P, Sparreboom A. Modulation of irinotecan metabolism by ketoconazole. J. Clin. Oncol. 20(14), 3122-3129 (2002).
27. Yong WP, Desai AA, Innocenti F et al. Pharmacokinetic modulation of oral etoposide by ketoconazole in patients with advanced cancer. Cancer Chemother. Pharmacol. 60(6), 811-819 (2007).
28. Relling MV, Evans R, Dass C, Desiderio DM, Nemec J. Human cytochrome P450 metabolism of teniposide and etoposide. J. Pharmacol. Exp. Ther. 261(2), 491-496 (1992).
29. Watanabe Y, Nakajima M, Ohashi N, Kume T, Yokoi T. Glucuronidation of etoposide in human liver microsomes is specifically catalyzed by UDP glucuronosyltransferase 1A1. Drug Metab. Dispos. 31(5), 589-595 (2003).
30. el-Yazigi A, Ezzat A, Berry J et al. Optimization of oral etoposide dosage in elderly patients with non-Hodgkin's lymphoma using the fraction of dose absorbed measured for each patient. J. Clin. Pharmacol. 40(2), 153-160 (2000).
31. Paredes J, Kahn JO, Tong WP et al. Weekly oral etoposide in patients with Kaposi's sarcoma associated with human immunodeficiency virus infection: A Phase I multicenter trial of the AIDS Clinical Trials Group. J. Acquir. Immune Defic. Syndr. Hum. Retrovirol. 9(2), 138-144 (1995).
32. Kang MH, Figg WD, Ando Y et al. The P-glycoprotein antagonist PSC 833 increases the plasma concentrations of 6alpha-hydroxypaclitaxel, a major metabolite of paclitaxel. Clin. Cancer Res. 7(6), 1610-1617 (2001).
33. Oostendorp RL, Beijnen JH, Schellens JH. The biological and clinical role of drug transporters at the intestinal barrier. Cancer Treat. Rev. 35(2), 137-147 (2009).
34. Kubota T. 5-fluorouracil and dihydropyrimidine dehydrogenase. Int. J. Clin. Oncol. 8(3), 127-131 (2003).
35. Grem JL, Harold N, Shapiro J et al. Phase I and pharmacokinetic trial of weekly oral fluorouracil given with eniluracil and low-dose leucovorin to patients with solid tumors. J. Clin. Oncol. 18(23), 3952-3963 (2000).
36. Schilsky RL, Levin J, West WH et al. Randomized, open-label, Phase III study of a 28-day oral regimen of eniluracil plus fluorouracil versus intravenous fluorouracil plus leucovorin as first-line therapy in patients with metastatic/advanced colorectal cancer. J. Clin. Oncol. 20(6), 1519-1526 (2002).
37. Shirasaka T, Shimamato Y, Ohshimo H et al. Development of a novel form of an oral 5-fluorouracil derivative (S-1) directed to the potentiation of the tumor selective cytotoxicity of 5-fluorouracil by two biochemical modulators. Anticancer Drugs 7(5), 548-557 (1996).
38. Lee JL, Kang YK, Kang HJ et al. A randomised multicentre Phase II trial of capecitabine vs S-1 as first-line treatment in elderly patients with metastatic or recurrent unresectable gastric cancer. Br. J. Cancer 99(4), 584-590 (2008).
39. Oostendorp RL, Huitema A, Rosing H et al. Coadministration of ritonavir strongly enhances the apparent oral bioavailability of docetaxel in patients with solid tumors. Clin. Cancer Res. 15(12), 4228-4233 (2009).
40. Prados MD, Yung WK, Jaeckle KA et al. Phase 1 trial of irinotecan (CPT-11) in patients with recurrent malignant glioma: A North American Brain Tumor Consortium study. Neuro. Oncol. 6(1), 44-54 (2004).
41. Bergshoeff AS, Wolfs TF, Geelen SP, Burger DM. Ritonavir-enhanced pharmacokinetics of nelfinavir/M8 during rifampin use. Ann. Pharmacother. 37(4), 521-525 (2003).
42. Innocenti F, Undevia SD, Ramirez J et al. A Phase I trial of pharmacologic modulation of irinotecan with cyclosporine and phenobarbital. Clin. Pharmacol. Ther. 76(5), 490-502 (2004).
43. Fuchs CS, Moore MR, Harker G, Villa L, Rinaldi D, Hecht JR. Phase III comparison of two irinotecan dosing regimens in second-line therapy of metastatic colorectal cancer. J. Clin. Oncol. 21(5), 807-814 (2003).
44. Shukla S, Ohnuma S, Ambudkar SV. Improving cancer chemotherapy with modulators of ABC drug transporters. Curr. Drug Targets 12(5), 621-630 (2011).
45. Varma MV, Ambler CM, Ullah M et al. Targeting intestinal transporters for optimizing oral drug absorption. Curr. Drug Metab. 11(9), 730-742 (2010).
46. Englund G, Rorsman F, Ronnblom A et al. Regional levels of drug transporters along the human intestinal tract: Co-expression of ABC and SLC transporters and comparison with Caco-2 cells. Eur. J. Pharm. Sci. 29(3-4), 269-277 (2006).
47. Sharom FJ. ABC multidrug transporters: Structure, function and role in chemoresistance. Pharmacogenomics 9(1), 105-127 (2008).
48. Shukla S, Wu CP, Ambudkar SV. Development of inhibitors of ATP-binding cassette drug transporters: Present status and challenges. Expert Opin Drug Metab. Toxicol. 4(2), 205-223 (2008).
49. Meerum Terwogt JM, Malingre MM, Beijnen JH et al. Coadministration of oral cyclosporin A enables oral therapy with paclitaxel. Clin. Cancer Res. 5(11), 3379-3384 (1999).
50. Malingre MM, Terwogt JM, Beijnen JH et al. Phase I and pharmacokinetic study of oral paclitaxel. J. Clin. Oncol. 18(12), 2468-2475 (2000).
51. Malingre MM, Beijnen JH, Rosing H et al. Co-Administration of GF120918 significantly increases the systemic exposure to oral paclitaxel in cancer patients. Br. J. Cancer 84(1), 42-47 (2001).
52. Malingre MM, Richel DJ, Beijnen JH et al. Coadministration of cyclosporine strongly enhances the oral bioavailability of docetaxel. J. Clin. Oncol. 19(4), 1160-1166 (2001).
53. Kuppens IE, Bosch TM, van Maanen MJ et al. Oral bioavailability of docetaxel in combination with OC144 093 (ONT-093). Cancer Chemother. Pharmacol. 55(1), 72-78 (2005).
54. Kruijtzer CM, Beijnen JH, Rosing H et al. Increased oral bioavailability of topotecan in combination with the breast cancer resistance protein and P-glycoprotein inhibitor GF120918. J. Clin. Oncol. 20(13), 2943-2950 (2002).
55. Kuppens IE, Witteveen EO, Jewell RC et al. A Phase I, randomized, open-label, parallel-cohort, dose-finding study of elacridar (GF120918) and oral topotecan in cancer patients. Clin. Cancer Res. 13(11), 3276-3285 (2007).
56. Kruijtzer CM, Schellens JH, Mezger J et al. Phase II and pharmacologic study of weekly oral paclitaxel plus cyclosporine in patients with advanced non-small-cell lung cancer. J. Clin. Oncol. 20(23), 4508-4516 (2002).
57. Bardelmeijer HA, Ouwehand M, Buckle T et al. Low systemic exposure of oral docetaxel in mice resulting from extensive first-pass metabolism is boosted by ritonavir. Cancer Res. 62(21), 6158-6164 (2002).
58. Schellens JH, Malingre MM, Kruijtzer CM et al. Modulation of oral bioavailability of anticancer drugs: From mouse to man. Eur. J. Pharm. Sci. 12(2), 103-110 (2000).
59. Chester JD, Joel SP, Cheeseman SL et al. Phase I and pharmacokinetic study of intravenous irinotecan plus oral ciclosporin in patients with fluorouracil-refractory metastatic colon cancer. J. Clin. Oncol. 21(6), 1125-1132 (2003).
60. Aherne GW, Piall E, Marks V, Mould G, White WF. Prolongation and enhancement of serum methotrexate concentrations by probenecid. Br. Med. J. 1(6120), 1097-1099 (1978).
61. Aherne GW, Marks V, Mould GP, Piall E, White WF. The interaction between methotrexate and probenecid in man [proceedings]. Br. J. Pharmacol. 63(2), 369P (1978).
62. Takeda M, Khamdang S, Narikawa S et al. Characterization of methotrexate transport and its drug interactions with human organic anion transporters. J. Pharmacol. Exp. Ther. 302(2), 666-671 (2002).
63. Krug LM, Ng KK, Kris MG et al. Phase I and pharmacokinetic study of 10-propargyl-10-deazaaminopterin, a new antifolate. Clin. Cancer Res. 6(9), 3493-3498 (2000).
64. Fury MG, Krug LM, Azzoli CG et al. A Phase I clinical pharmacologic study of pralatrexate in combination with probenecid in adults with advanced solid tumors. Cancer Chemother. Pharmacol. 57(5), 671-677 (2006).
65. Dorr R, Karanes C, Spier C et al. Phase I/II study of the P-glycoprotein modulator PSC 833 in patients with acute myeloid leukemia. J. Clin. Oncol. 19(6), 1589-1599 (2001).
66. Leonard GD, Fojo T, Bates SE. The role of ABC transporters in clinical practice. Oncologist 8(5), 411-424 (2003).
67. Geyer CE, Forster J, Lindquist D et al. Lapatinib plus capecitabine for HER2-positive advanced breast cancer. N. Engl. J. Med. 355(26), 2733-2743 (2006).
68. Gomez HL, Doval DC, Chavez MA et al. Efficacy and safety of lapatinib as first-line therapy for ErbB2-Amplified locally advanced or metastatic breast cancer. J. Clin. Oncol. 26(18), 2999-3005 (2008).
69. Steinherz PG, Seibel NL, Ames MM et al. Phase I study of gemcitabine (difluorodeoxycytidine) in children with relapsed or refractory leukemia (CCG-0955): A report from the Children's Cancer Group. Leuk. Lymphoma 43(10), 1945-1950 (2002).
70. Soo RA, Lim HL, Wang LZ et al. Phase I trial of fixed dose-rate gemcitabine in combination with carboplatin in chemonaive advanced non-small-cell lung cancer: A Cancer Therapeutics Research Group study. Cancer Chemother. Pharmacol. 52(2), 153-158 (2003).
71. Soo RA, Wang LZ, Tham LS et al. A multicentre randomised Phase II study of carboplatin in combination with gemcitabine at standard rate or fixed dose rate infusion in patients with advanced stage non-small-cell lung cancer. Ann. Oncol. 17(7), 1128-1133 (2006).
72. Kang SP, Ratain MJ. Inconsistent labeling of food effect for oral agents across therapeutic areas: Differences between oncology and non-oncology products. Clin. Cancer Res. 16(17), 4446-4451 (2010).
73. Jain RK, Brar SS, Lesko LJ. Food and oral antineoplastics: More than meets the eye. Clin. Cancer Res. 16(17), 4305-4307 (2010).
74. Koch KM, Reddy NJ, Cohen RB et al. Effects of food on the relative bioavailability of lapatinib in cancer patients. J. Clin. Oncol. 27(8), 1191-1196 (2009).
75. Tannock IF. Effects of food on bioavailability of lapatinib: Useful data, wrong conclusion. J. Clin. Oncol. 27(22), e42; author reply e43 (2009).
76. Ratain MJ. Flushing oral oncology drugs down the toilet. J. Clin. Oncol. 29(30), 3958-3959 (2011).